Skip to main content

Targeting the intestinal barrier in GVHD and checkpoint colitis

Published on October 29, 2026   20 min

Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms

Please wait while the transcript is being prepared...
0:00
Hello. My name is Robert Zeiser. I'm the Director of the Division of Tumor immunology and Stem Cell Transplantation at Freiburg University Medical Center. Today I will talk about Therapeutic Targeting of the Intestinal Barrier in GVHD and Immune Checkpoint-induced Colitis.
0:23
These are my disclosures.
0:26
Acute graft-versus-host disease has a clinical presentation that the skin can be affected, the intestinal tract, and the liver. When you look at these images here, you can see that this patient has a rash indicative of tissue inflammation in the skin. Then, the next images show you here, endoscopic view into the intestinal tract of patients with early intestinal GVHD or more advanced acute intestinal GVHD. When you biopsy these organs, you would find in the skin apoptotic cells in the basal membrane of the skin. In the liver biopsy you would find infiltration of the small bile ducts with lymphocytes, and in the colon biopsies you would find apoptotic cells.
1:12
What is the response to steroids in patients with acute GVHDs? Steroids are effective in only 40% of patients with acute GVHD and only 30% of the patients with acute GVHD have a long lasting response to corticosteroids.
1:30
Does GVHD impact survival? Here you see the mortality of patients with intestinal steroid-refractory acute GVHD, and as you can see, mortality is above 50% at three years. In order to better treat this disease,

Quiz available with full talk access. Request Free Trial or Login.

Show
Hide

Targeting the intestinal barrier in GVHD and checkpoint colitis

Embed in course/own notes